FDA

News

Merck & Co's Keytruda gets new colorectal cancer use after m...

It’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal cancer patients with certain mutations, and th

News

Intercept CEO lays into FDA after NASH drug rejection

Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection.

News

FDA approves Akili's video game ADHD therapy

The FDA has approved the first video game-based treatment for attention deficit hyperactivity disorder (ADHD), from Akili.

News

hydroxychloroquine sulphate tablets, in evaluation for treatment of COVID-19.Denmark, Mars 22, 2020

FDA defies Trump and revokes emergency authorisation for hyd...

The FDA has revoked its Emergency Use Authorization for hydroxychloroquine as a treatment for COVID-19, drawing the ire of president Donald Trump who has repeatedly backed the drug despite

News

FDA extends review of Novartis' MS drug ofatumumab

The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year.

News

FDA hastens development of Novartis' Kymriah in follicular l...

Novartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah for follicular lymphoma, after the regulator deemed it to be an advanced regene

Merck & Co's Keytruda gets new colorectal cancer use after m...

Intercept CEO lays into FDA after NASH drug rejection

FDA approves Akili's video game ADHD therapy

FDA defies Trump and revokes emergency authorisation for hyd...

FDA extends review of Novartis' MS drug ofatumumab

FDA hastens development of Novartis' Kymriah in follicular l...

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks